NEULANDLAB - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Investment Rating: 3.7

🧪 Fundamental Analysis: Neuland Laboratories Ltd. (NEULANDLAB)

Neuland Labs is a niche API manufacturer with strong R&D capabilities and a history of innovation. However, its current valuation is stretched, and recent earnings volatility raises caution for long-term investors.

Metric Value Implication

P/E Ratio 85.3 Very expensive vs. industry PE of 34 — pricing in aggressive future growth

PEG Ratio 1.80 Fair — growth is somewhat justified but not cheap

ROE / ROCE 14.8% / 18.7% Healthy — but not exceptional for a high-growth pharma stock

Dividend Yield 0.09% Negligible — not suitable for income investors

Debt-to-Equity 0.10 Excellent — low leverage supports long-term stability

EPS ₹203 Strong — but recent profit dip is concerning

Profit Growth (QoQ) -51.4% Sharp decline — needs monitoring

📈 Technical & Trend Analysis

Current Price: ₹13,840

DMA 50 / DMA 200: ₹12,867 / ₹12,213 — bullish trend intact

RSI: 58.1 — neutral to slightly bullish

MACD: +445 — strong momentum

Volume: Slightly below average — cautious accumulation

✅ Long-Term Investment Potential

Moderately attractive. Neuland Labs has strong fundamentals and low debt, but its valuation is rich and earnings volatility is a concern. Suitable for growth-oriented investors with a high-risk tolerance.

🎯 Ideal Entry Price Zone

Buy Zone: ₹12,200–₹13,000

Near 200-DMA and below recent highs

Accumulate only if PEG drops below 1.5 and ROCE improves above 20%

Avoid fresh entry above ₹14,500 unless earnings stabilize

🧭 Exit Strategy & Holding Period

If you're already holding

Holding Period: 2–3 years — to capture innovation-led growth

Exit Strategy

Partial Exit near ₹17,500–₹18,000 if P/E remains >80 and PEG exceeds 2

Hold if ROE stays above 15% and PAT growth resumes

Reassess if earnings continue to decline or institutional interest weakens

Would you like a curated list of mid-cap pharma stocks with more consistent earnings and better PEG ratios for long-term compounding?

Edit in a page